bit bio restarts with new management
Cell reprogramming specialist bit bio has expanded its management with renowned experts in the field.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1999 entries already.
Entries by Thomas Gabrielczyk
BioVersys receives up to €8m from CARB-X
Swiss biotech company BioVersys AG has received a €8m grant by US-based non-profit organisation CARB-X to develop novel anti-virulence antibiotics to treat severe bacterial infections.
Researchers identify viral inflammation switch
A team of Japanese and German researchers has found the protein that helps activate the inflammasome following viral invasion.
Rotavirus vaccines kill cancer cells
Researchers at University Lyon have found a potential repurposing application of two market-approved rotavirus vaccines.
Polyphor presents AMR breaker
Swiss Polyphor AG and researchers from the University of Zurich have presented the mechanism of action of a new class of antibiotics.
The AMR business (Part II)
SMEs active in antibiotic development are trying to adapt to the uncertain AMR business. Meanwhile, the European IMI AMR accelerator kicked off.
Zealand Pharma acquires Encycle
Zealand Pharma A/S has acquired Encycle Therapeutics Inc, including a peptide therapeutics platform and library.
The AMR business (Part I)
Antibiotic developers struggle with uncertain market conditions, weak reimbursement schemes and low turnover once a drug is approved. Experts are trying to figure out the best way to balance push and pull incentives.
Researchers target ferroptosis resistance of cancer cells
German researchers have found a novel way to induce iron-induced necrosis, a process which they want to turn against cancer.
CHMP selects drugs for EU market approval
EMA’s human medicines committee (CHMP) recommended seven medicines for approval at its October 2019 meeting.